Western blot analysis of tumor lysates harvested on day 26 confirmed that αEGFR-E-P125A–treated tumors demonstrated decreased phosphorylation of EGFR at Y1069, FAK at Y397, and STAT3 at Y705 compared with controls (Fig. 7F). The gene discussed is PTK2; the disease is neoplasm.